title: Decreased quality of peripheral blood progenitors collected after a peripheral blood progenitor transplant.
abstract: The purpose of this study was to determine the quality of peripheral blood progenitor cells (PBPC) collected after an initial autologous PBPC transplant. Tandem autologous transplants have been used in the treatment of several malignancies. Routinely, PBPC have been collected prior to the first transplant and used for both transplants. In the current study, PBPC harvested prior to the first high-dose therapy (HDT) were used as a source of progenitors for transplant 1, and a combination of bone marrow harvested prior to the first course of HDT and PBPC collected approximately 85 days after the first transplant were used to support the second HDT. We analyzed the quality of the PBPC collected 85-120 days after HDT and autologous PBPC transplant. CD34 and colony-forming units granulocyte-macrophage (CFU-GM) contents of those collections were poor, and hematopoietic recovery was more consistent with recovery from a bone marrow transplant than a PBPC transplant. Thirteen of 15 patients received both transplants. Days to absolute granulocyte count of 500 was 10 +/- 1.5 for the first transplant and 13.3 +/- 3.7 for the second (p < 0.01). The number of days to platelet count of 20,000 was 14.3 +/- 10.7 for the first transplant and 18 +/- 7 for the second transplant (p = 0.066). The number of days of total parenteral nutrition (TPN) and intravenous morphine used by patients for the first and second transplants was similar, whereas the length of hospitalization was 21.8 +/- 3.6 for the first transplant and 27.6 +/- 7.8 for the second transplant (NS). In conclusion, it appears that the quality of PBPC collected following a previous PBPC transplant may be compromised.
authors.affiliation: Tulane University Medical Center, New Orleans, LA 70112, USA. amiller@mailhost.tcs.tulane.edu
authors.forename: A
authors.initials: A
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Morrison
authors.forename: H
authors.initials: H
authors.lastname: Safah
authors.forename: S
authors.initials: S
authors.lastname: Cullins
authors.forename: V
authors.initials: V
authors.lastname: Larussa
authors.forename: J
authors.initials: J
authors.lastname: Rink
authors.forename: R
authors.initials: R
authors.lastname: Weiner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001781:Blood Component Removal; D001792:Blood Platelets / Q000166:cytology; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000592:standards; D001943:Breast Neoplasms / Q000628:therapy; D005260:Female; D006085:Graft Survival; D006098:Granulocytes / Q000166:cytology; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000592:standards*; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006760:Hospitalization; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage; D009092:Mucous Membrane; D010288:Parenteral Nutrition
chemical_list: D009020:Morphine